Accumulating evidence shows that although PD-L1 expression has been associated with cancer immune response in some patients submitted to immunotherapy, tumor HLA-I expression is the crucial factor driving the positive response and determining the efficacy of the therapy [181]. Here, CD274 is linked to neoplasm.